Civitas Therapeutics Obtains $55,000,000 Series C Financing

  • Feed Type
  • Date
    8/25/2014
  • Company Name
    Civitas Therapeutics
  • Mailing Address
    190 Everett Ave. Chelsea, MA 02150 USA
  • Company Description
    Civitas is a pharmaceutical company focused on developing products with a clinically proven dry powder pulmonary delivery platform. The proprietary dry powder and device combination is unique in its ability to deliver a large, precise dose independent of inspiratory flow rate from a simple, passive device.
  • Website
    http://www.civitastherapeutics.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $55,000,000
  • Transaction Round
    Series C
  • Proceeds Purposes
    The proceeds from this financing round will be used towards the upcoming Phase 3 clinical trials for our lead candidate, CVT-301, an inhaled formulation of levodopa (L-dopa) being developed for rapid and reliable relief from debilitating motor fluctuations, known as OFF episodes, associated with Parkinson’s disease (PD), as well as for the development of additional, early stage pipeline programs.
  • M&A Terms
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor

Trending on Xconomy